TP53 and lung adenocarcinoma: Studies show that mutations in TP53 were associated with an increased PD-L1 expression and co-occurrence of KRAS and TP53 mutation could predict response to PD-1 blockades in lung adenocarcinoma (Dong et al., 2017).